Abstract
Objectives
Design
Setting and Participants
Methods
Results
Conclusions and Implications
Keywords
- Cochard H.
- Aubier B.
- Quentin R.
- et al.
Methods
Selection of Institutions and Residents, and Ethical Approval
Study Design and Procedures
European Centre for Disease Prevention and Control (ECDC). Protocol for point prevalence surveys of healthcare-associated infections and antimicrobial use in European long-term care facilities. Version 2.1. Stockholm: ECDC. 2016. Available at: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/HALT-3-LTCF-PPS-Protocol-v2.1.pdf.
Microbiology Processing
Whole Genome Sequencing and Definition of Clusters
Data Analysis and Statistics
Results
Institutions and Residents
Characteristics | Screening (n = 606) | No Screening (n = 579) | P Value |
---|---|---|---|
West (canton of Vaud) | 265 (43.7) | 320 (55.3) | <.001 |
Age, y, mean (SD) | 84.1 (11) | 84.9 (33) | .57 |
Female | 411 (67.8) | 426 (73.6) | .035 |
Urinary catheter | 83 (13.7) | 28 (4.8) | <.001 |
Incontinence | 396 (65.3) | 364 (62.9) | .41 |
Decubitus | 22 (3.6) | 17 (2.9) | .61 |
Other wound | 52 (8.6) | 43 (7.4) | .53 |
Disoriented | 325 (53.6) | 303 (52.3) | .70 |
Dementia | 270 (44.6) | 275 (47.5) | .34 |
Wheelchair or bedbound | 225 (37.1) | 185 (32.0) | .07 |
Surgery previous 30 d | 7 (1.2) | 4 (0.7) | .60 |
Proton-pump inhibitor | 210 (34.6) | 206 (35.6) | .79 |
Antibiotic treatment | 16 (2.6) | 18 (3.1) | .76 |
Prevalence, Coresistances, and Molecular Epidemiology

Clustering of ESBL-E Within and Between LTCFs

Risk Factors for ESBL-E and for ESBL–E coli ST131
Characteristics | ESBL Negative (n = 536) | ESBL Positive (n = 70) | Univariable Logistic Regression | Multivariable Logistic Regression | ||
---|---|---|---|---|---|---|
OR (95% CI) | P Value | OR (95% CI) | P Value | |||
Western Switzerland | 227 (42.4) | 38 (54.3) | 1.8 (0.8-3.9) | .13 | NA | NA |
Age, y, median (IQR) | 87 (80-92) | 84.5 (70-89) | 0.97 (0.95-0.99) | .006 | 0.99 (0.96-1.00) | .46 |
Male sex | 157 (29.3) | 38 (54.3) | 3.0 (1.8-5.0) | <.001 | 2.6 (1.5-4.6) | .001 |
Urinary catheter | 67 (12.5) | 16 (22.9) | 1.7 (0.9-3.3) | .10 | NA | NA |
Decubitus | 18 (3.4) | 4 (5.7) | 1.5 (0.5-4.6) | .53 | NA | NA |
Wound | 47 (8.8) | 5 (7.1) | 0.8 (0.3-2.1) | .66 | NA | NA |
Wheelchair or bedbound | 193 (36.0) | 32 (45.7) | 1.4 (0.8-2.4) | .22 | NA | NA |
Incontinence | 346 (64.6) | 50 (70.4) | 1.4 (0.8-2.4) | .27 | NA | NA |
Disorientation | 291 (54.3) | 34 (47.9) | 0.9 (0.5-1.5) | .64 | NA | NA |
Dementia | 240 (44.8) | 30 (42.3) | 1.0 (0.6-1.7) | .91 | NA | NA |
Years in facility, median (IQR) | 2 (1-5) | 2.5 (1-5) | 1.0 (0.9-1.1) | .66 | NA | NA |
Katz-Score, median (IQR) | 16 (10-20) | 17 (13-21) | 1.03 (0.98-1.08) | .21 | NA | NA |
Proton-pump inhibitor | 175 (32.6) | 35 (50.0) | 2.2 (1.3-3.6) | .003 | 2.2 (1.2-3.8) | .007 |
Previous ESBL detection | 5 (0.9) | 12 (17.1) | 29.6 (9.0-97.2) | <.001 | 23.5 (6.6-83.8) | <.001 |
Previous hospital admission | 88 (16.4) | 17 (24.3) | 1.6 (0.9-3.0) | .13 | NA | NA |
Previous endoscopy | 8 (1.5) | 1 (1.4) | 1.3 (0.2-10.8) | .84 | NA | NA |
Previous antibiotic treatment | 175 (32.6) | 33 (47.1) | 1.7 (1.0-2.9) | .04 | 1.2 (0.7-2.1) | .57 |
Discussion
- Overdevest I.
- Haverkate M.
- Veenemans J.
- et al.
Conclusion and Implications
Acknowledgments
Supplementary Data
Characteristics | High Prevalence (Median 13.4%) (n = 8) | Low Prevalence (Median 6.9%) (n = 8) | P Value |
---|---|---|---|
General information | |||
Western Switzerland | 6 (75.0) | 2 (25.0) | .13 |
Ownership | .80 | ||
Public | 1 (12.5) | 2 (25.0) | |
Not for profit | 5 (62.5) | 4 (50.0) | |
For profit | 2 (25.0) | 2 (25.0) | |
Occupied beds at time of survey | 73.50 (21.99) | 75.00 (14.71) | .88 |
Qualified nursing care available 24 h | 3 (37.5) | 1 (12.5) | .56 |
FTE nursing assistants, %, mean (SD) | 44.13 (11.70) | 50.08 (11.43) | .32 |
FTE per occupied bed, mean (SD) | 0.36 (0.20) | 0.55 (0.24) | .11 |
Single beds, %, mean (SD) | 76.39 (23.63) | 64.58 (23.97) | .34 |
Medical care | .27 | ||
Both | 5 (62.5) | 3 (37.5) | |
Personal general practitioners (GPs) | 1 (12.5) | 4 (50.0) | |
Medical staff employed by the facility | 2 (25.0) | 1 (12.5) | |
Residents | |||
Katz score, median (IQR) | 16.50 (3.04) | 15.12 (2.63) | .35 |
Age >85 y, %, mean (SD) | 55.58 (25.87) | 55.44 (13.95) | .99 |
Consent for screening, %, mean (SD) | 46.71 (10.54) | 55.28 (10.17) | .12 |
Infection control practice | |||
Trained persons in infection control and prevention | 8 (100.0) | 8 (100.0) | NA |
Infection prevention training for nurses | 1 (12.5) | 1 (12.5) | >.99 |
Infection prevention training for non-nurses | 6 (75.0) | 2 (25.0) | .13 |
Infection control committee | 6 (75.0) | 3 (37.5) | .31 |
Hand hygiene training | 2 (25.0) | 0 (0.0) | .45 |
Liters of alcohol rub solution in 2018/bed, mean (SD) | 3.70 (2.15) | 6.94 (5.39) | .17 |
Antimicrobial policy | |||
Therapeutic guidelines available | 2 (25.0) | 5 (62.5) | .31 |
Pharmacist advice for antimicrobials | 5 (62.5) | 7 (87.5) | .56 |
Microbiology laboratory in charge of institution | .14 | ||
One | 5 (62.5) | 4 (50.0) | |
More than 1 | 2 (25.0) | 0 (0.0) | |
None, this is done directly by the GP | 1 (12.5) | 4 (50.0) |
ID | Species | AMC | TZP | CAZ | FEP | ATM | IMI | MER | AM | TBM | NOR | CIP | LVX | FOS | NF | SXT | ST | β-Lactamase- Gene | bla-Class A Genes (I) | bla-Class A Gene (II) | bla-Class D Gene | bla-misc. Groups | fim Type |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SG-01-007 | Proteus mirabilis | R | S | R | R | S | R | R | S | S | R | R | R | S | n.a. | R | 35 | blaCTX-M-36 | |||||
SG-01-046 | Klebsiella pneumoniae | R | S | R | R | R | S | S | S | S | R | R | I | S | n.a. | R | 1190 | blaCTX-M-15 | blaSHV-106 | blaTEM-1 | |||
SG-02-012 | Citrobacter farmeri | R | S | S | S | R | S | S | S | S | S | S | S | S | n.a. | S | blaSED | ||||||
SG-02-014 | Escherichia coli | R | S | I | R | R | S | S | S | S | S | S | S | S | S | R | 38 | blaEC-8 | blaCTX-M-9 | ||||
SG-02-052 | E coli | S | S | I | I | I | S | S | S | S | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-27 | fimH30 | |||
SG-02-057 | E coli | S | S | I | I | I | S | S | S | S | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-27 | fimH30 | |||
SG-02-091 | E coli | S | S | I | I | I | S | S | S | S | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-27 | fimH41 | |||
SG-02-093 | E coli | S | S | I | I | I | S | S | S | S | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-27 | fimH41 | |||
SG-03-058 | E coli | R | S | I | R | R | S | S | S | R | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH30 | ||
SG-03-066 | E coli | S | S | R | I | R | S | S | S | S | R | R | R | S | S | R | unk | blaEC-5 | blaCTX-M-27 | ||||
SG-03-086 | E coli | S | S | I | R | R | S | S | S | R | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-27 | fimH30 | |||
SG-03-089 | E coli | S | S | I | R | R | S | S | S | S | I | S | S | S | S | S | 38 | blaEC-8 | blaCTX-M-15 | ||||
SG-04-028 | Klebsiella oxytoca | S | S | R | S | R | S | S | S | S | S | S | S | S | n.a. | S | 224 | blaOXY-6-1 | blaSHV-12 | ||||
SG-05-062 | E coli | R | S | I | R | R | S | S | S | S | S | S | S | S | S | S | 53 | blaEC-18 | blaCTX-M-1 | ||||
SG-05-063 | E coli | R | S | I | I | I | S | S | S | S | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-1 | blaTEM-1 | fimH412 | ||
SG-06-055 | E coli | R | S | S | I | I | S | S | S | S | I | I | I | S | S | R | 10 | blaEC | blaCTX-M-14 | ||||
SG-06-061 | E coli | R | I | R | R | R | S | S | S | R | R | R | R | S | S | R | 3643 | blaEC-15 | blaTEM-40 | ||||
SG-07-030 | K pneumoniae | R | S | R | R | R | S | S | S | R | R | R | R | R | n.a. | S | 307 | blaCTX-M-15 | blaSHV-106 | blaOXA-1 | blaTEM-1 | ||
SG-07-034 | K pneumoniae | R | S | R | I | R | S | S | S | R | R | R | R | R | n.a. | S | 307 | blaCTX-M-15 | blaSHV-106 | blaOXA-1 | blaTEM-1 | ||
SG-08-008 | E coli | S | S | I | I | R | S | S | S | S | S | S | S | S | S | S | 69 | blaEC-8 | blaCTX-M-15 | ||||
SG-08-010 | E coli | S | S | R | R | R | S | S | S | S | R | R | R | S | S | R | 501 | blaEC-8 | blaCTX-M-15 | ||||
SG-08-016 | E coli | S | S | I | R | R | S | S | S | S | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-27 | fimH30 | |||
SG-08-032 | E coli | R | S | I | R | R | S | S | S | S | S | S | S | S | S | S | 69 | blaEC-8 | blaCTX-M-15 | ||||
SG-08-033 | E coli | R | S | S | R | I | S | S | S | R | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH30 | ||
SG-08-037 | E coli | R | S | I | R | R | S | S | S | S | S | S | S | S | S | S | 69 | blaEC-8 | blaCTX-M-15 | ||||
SG-08-041 | E coli | R | S | I | R | R | S | S | S | S | S | S | S | S | S | S | 69 | blaEC-8 | blaCTX-M-15 | ||||
SG-08-042 | E coli | R | S | I | R | I | S | S | S | R | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH30 | ||
SG-08-045 | E coli | S | S | R | R | R | S | S | S | S | S | S | S | S | S | S | 69 | blaEC-8 | blaCTX-M-15 | ||||
SG-08-047 | E coli | R | S | I | R | R | S | S | S | R | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH30 | ||
SG-08-055 | E coli | R | S | S | I | I | S | S | S | R | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH30 | ||
SG-08-058 | E coli | R | S | I | R | I | S | S | S | R | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-14 | fimH30 | |||
SG-08-059 | E coli | R | S | I | R | I | S | S | S | R | R | R | R | S | S | S | 69 | blaEC-5 | blaCTX-M-14 | ||||
SG-08-059 | E coli | R | S | I | R | I | S | S | S | R | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-14 | fimH30 | |||
VD-01-001 | E coli | R | S | R | R | R | S | S | S | S | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-15 | blaTEM-1 | fimH30 | ||
VD-01-014 | E coli | R | S | R | R | R | S | S | S | S | I | I | I | S | S | S | 131 | blaEC-5 | blaCTX-M-55 | fimH41 | |||
VD-01-063 | E coli | R | S | R | R | R | S | S | S | R | R | R | R | S | n.d. | R | 131 | blaEC-5 | blaCTX-M-15 | blaTEM-1 | fimH41 | ||
VD-01-078 | K pneumoniae | R | S | R | S | R | S | S | S | S | R | R | R | S | n.a. | S | blaSHV-33 | ||||||
VD-01-096 | E coli | S | S | R | R | R | S | S | S | S | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-27 | fimH30 | |||
VD-02-015 | E coli | R | S | R | I | R | S | S | S | S | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-27 | fimH30 | |||
VD-02-026 | E coli | S | S | R | I | R | S | S | S | S | R | R | R | S | R | R | 131 | blaEC-5 | blaCTX-M-27 | fimH30 | |||
VD-02-033 | E coli | S | S | I | I | R | S | S | S | S | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-27 | fimH30 | |||
VD-02-068 | E coli | R | S | I | I | R | S | S | S | R | I | I | S | S | S | R | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH89 | ||
VD-02-083 | E coli | R | S | I | R | R | S | S | S | R | I | I | S | S | S | R | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH89 | ||
VD-02-092 | E coli | S | S | I | I | R | S | S | S | S | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-27 | fimH30 | |||
VD-03-042 | E coli | S | S | I | R | R | S | S | S | S | R | R | R | S | S | S | nd | nd | |||||
VD-03-050 | E coli | S | S | I | I | R | S | S | S | S | R | R | R | S | S | R | nd | nd | |||||
VD-04-008 | E coli | R | S | S | S | S | S | S | S | S | S | S | S | S | S | S | nd | nd | |||||
VD-04-016 | E coli | R | S | I | I | R | S | S | S | R | I | I | S | S | S | R | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH89 | ||
VD-04-027 | E coli | S | S | R | I | R | S | S | S | S | R | R | R | S | S | R | 131 | blaEC-5 | blaCTX-M-27 | fimH30 | |||
VD-04-035 | E coli | S | S | R | I | R | S | S | S | S | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-27 | fimH30 | |||
VD-04-071 | E coli | R | S | I | I | R | S | S | S | R | I | I | I | S | S | S | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH89 | ||
VD-05-002 | E coli | R | S | I | R | I | S | S | S | S | S | S | S | S | S | S | 131 | blaEC-5 | blaCTX-M-14 | fimH41-like | |||
VD-05-017 | E coli | R | S | R | R | R | S | S | S | S | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-15 | blaTEM-1 | fimH30 | ||
VD-05-023 | E coli | R | S | S | R | I | S | S | S | S | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH30 | ||
VD-05-026 | E coli | R | S | S | R | I | S | S | S | S | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH30 | ||
VD-05-035 | E coli | R | S | I | I | R | S | S | S | R | I | I | I | S | S | S | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH89 | ||
VD-05-042 | K pneumoniae | R | I | R | R | R | S | S | S | R | R | R | R | S | n.a. | R | 235 | blaLAP-2 | blaCTX-M-15 | blaSHV-145 | blaOXA-1 | ||
VD-05-043 | E coli | S | S | S | I | I | S | S | S | R | S | S | S | S | S | S | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH41-like | ||
VD-05-059 | E coli | R | I | R | R | R | S | S | S | R | R | R | R | S | R | R | 6938 | blaEC-15 | blaCTX-M-15 | blaTEM-1 | |||
VD-05-065 | E coli | S | S | R | R | R | S | S | S | S | I | I | S | S | S | R | 69 | blaEC-8 | blaCTX-M-15 | blaTEM-1? | |||
VD-06-040 | E coli | R | S | I | R | R | S | S | S | S | R | I | I | S | S | S | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH89 | ||
VD-06-048 | E coli | R | S | I | I | R | S | S | S | R | I | I | I | S | S | R | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH89 | ||
VD-06-061 | E coli | R | S | I | I | R | S | S | S | R | I | I | S | S | S | R | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH89 | ||
VD-07-011 | E coli | R | S | I | R | R | S | S | S | S | I | S | S | S | S | S | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH89 | ||
VD-07-025 | E coli | R | S | R | R | R | S | S | S | R | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-15 | blaOXA-1 | fimH30 | ||
VD-07-035 | E coli | R | S | R | R | R | S | S | S | R | R | R | R | S | S | R | 8347 | blaEC-5 | blaCTX-M-15 | blaOXA-1 | blaTEM-1 | ||
VD-08-031 | E coli | S | S | R | R | R | S | S | S | S | R | R | R | S | S | S | 131 | blaEC-5 | blaCTX-M-27 | fimH30 | |||
VD-08-032 | E coli | R | S | I | I | R | S | S | S | R | I | I | S | S | S | S | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH89 | ||
VD-08-058 | E coli | R | S | I | R | R | S | S | S | R | I | I | S | S | S | R | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH89 | ||
VD-08-067 | E coli | R | S | I | I | R | S | S | S | R | I | I | S | S | S | S | 131 | blaEC-5 | blaCTX-M-14 | blaTEM-1 | fimH89 | ||
VD-08-068 | E coli | R | S | I | I | R | S | S | S | S | I | I | S | S | S | R | nd | nd |
Characteristics | ST131 (n = 42) | Other ST (n = 14) | P Value |
---|---|---|---|
Western Switzerland | 29 (69.0) | 2 (14.3) | .001 |
Age, median (IQR) | 85 (69-91) | 84 (75-87) | .59 |
Female sex | 17 (40.5) | 9 (64.3) | .22 |
Urinary catheter | 10 (23.8) | 2 (14.3) | .71 |
Incontinence | 32 (76.2) | 9 (64.3) | .60 |
Decubitus | 4 (9.5) | 0 (0.0) | .55 |
Wound | 4 (9.5) | 0 (0.0) | .55 |
Disorientation | 23 (54.8) | 4 (28.6) | .17 |
Dementia | 18 (42.9) | 5 (35.7) | .88 |
Wheelchair or bedbound | 21 (50.0) | 5 (35.7) | .54 |
Proton-pump inhibitor | 22 (52.4) | 8 (57.1) | >.99 |
Previous endoscopy | 0 (0.0) | 0 (0.0) | NA |
Previous hospital admission | 9 (21.4) | 3 (21.4) | >.99 |
Previous ESBL | 8 (19.0) | 0 (0.0) | .19 |
Previous antibiotic treatment | 19 (45.2) | 4 (28.6) | >.99 |
Years in facility, median (IQR) | 3 (1-4) | 1.5 (1.5-7.5) | .88 |
Katz-score, median (IQR) | 18 (16-21) | 18 (8-21) | .34 |


References
- Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.JAMA. 1999; 281: 517-523
- The SHIELD Orange County Project: Multidrug-resistant organism prevalence in 21 nursing homes and long-term acute care facilities in southern California.Clin Infect Dis. 2019; 69: 1566-1573
- The role of nursing homes in the spread of antimicrobial resistance over the healthcare network.Infect Control Hosp Epidemiol. 2016; 37: 761-767
- Long-term care facilities are reservoirs for antimicrobial-resistant sequence type 131 Escherichia coli.Open Forum Infect Dis. 2015; 2: ofv011
- Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts.Infect Control Hosp Epidemiol. 2013; 34: 361-369
- Prevalence, genetic diversity of and factors associated with ESBL-producing Enterobacterales carriage in residents of French nursing homes.J Hosp Infect. 2020; 104: 469-475
- Characteristics of urinary tract infections in older patients in a tertiary hospital in Greece.Geriatr Gerontol Int. 2020; 20: 1228-1233
- Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis.J Antimicrob Chemother. 2007; 60: 913-920
- The impact of carbapenem resistance on mortality in patients with Klebsiella pneumoniae bloodstream infection: An individual patient data meta-analysis of 1952 patients.Infect Dis Ther. 2021; 10: 541-558
- Antibiotic resistance in Swiss nursing homes: Analysis of National Surveillance Data over an 11-year period between 2007 and 2017.Antimicrob Resist Infect Control. 2018; 7: 88
- Review on colonization of residents and staff in Italian long-term care facilities by multidrug-resistant bacteria compared with other European countries.Antimicrob Resist Infect Control. 2016; 5: 33
- Colonization by multidrug-resistant organisms in long-term care facilities in Italy: A point-prevalence study.Clin Microbiol Infect. 2017; 23: 961-967
- Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria.Clin Microbiol Infect. 2010; 16: 934-944
- Prevalence of methicillin-resistant Staphylococcus aureus colonization among older residents of care homes in the United Kingdom.Infect Control Hosp Epidemiol. 2007; 28: 853-859
- Evaluation of the association between gastric acid suppression and risk of intestinal colonization with multidrug-resistant microorganisms: A systematic review and meta-analysis.JAMA Intern Med. 2020; 180: 561-571
- Extended-spectrum β-lactamase-producing Enterobacteriaceae in French nursing homes: An association between high carriage rate among residents, environmental contamination, poor conformity with good hygiene practice, and putative resident-to-resident transmission.Infect Control Hosp Epidemiol. 2014; 35: 384-389
- The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae.Clin Infect Dis. 2013; 57: 1246-1252
- SHEA/APIC guideline: Infection prevention and control in the long-term care facility, July 2008.Infect Control Hosp Epidemiol. 2008; 29: 785-814
- Antibiotic-resistant pathogens in different patient settings and identification of surveillance gaps in Switzerland—a systematic review.Epidemiol Infect. 2019; 147: e259
- Universal screening and decolonization for control of MRSA in nursing homes: follow-up of a cluster randomized controlled trial.J Hosp Infect. 2017; 96: 69-71
European Centre for Disease Prevention and Control (ECDC). Protocol for point prevalence surveys of healthcare-associated infections and antimicrobial use in European long-term care facilities. Version 2.1. Stockholm: ECDC. 2016. Available at: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/HALT-3-LTCF-PPS-Protocol-v2.1.pdf.
- Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function.JAMA. 1963; 185: 914-919
- Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads.PLoS Comput Biol. 2017; 13: e1005595
- Development of a web tool for Escherichia coli subtyping based on fimH alleles.J Clin Microbiol. 2017; 55: 2538-2543
- The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. Parkhill J, ed.mBio. 2013; 4: e00377-13
- Prevalence and genetic diversity of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in nursing homes in Bavaria, Germany.Vet Microbiol. 2017; 200: 138-141
- Colonization of long term care facility patients with MDR-gram-negatives during an Acinetobacter baumannii outbreak.Antimicrob Resist Infect Control. 2017; 6: 49
- Extended-spectrum β-lactamase-producing Enterobacteriaceae colonisation in long-term care facilities: A systematic review and meta-analysis.Int J Antimicrob Agents. 2017; 50: 649-656
- Use of whole-genome sequencing to trace, control and characterize the regional expansion of extended-spectrum β-lactamase producing ST15 Klebsiella pneumoniae.Sci Rep. 2016; 6: 20840
- Clonal or not clonal? Investigating hospital outbreaks of KPC-producing Klebsiella pneumoniae with whole-genome sequencing.Clin Microbiol Infect. 2017; 23: 470-475
- Colonisation with ESBL-producing and carbapenemase-producing Enterobacteriaceae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus in a long-term care facility over one year.BMC Infect Dis. 2015; 15: 168
- Prolonged colonisation with Escherichia coli O25:ST131 versus other extended-spectrum beta-lactamase-producing E. coli in a long-term care facility with high endemic level of rectal colonisation, The Netherlands, 2013 to 2014.Euro Surveill. 2016; 21: 30376
- Emergence of diversity in carbapenemase-producing Escherichia coli ST131, England, January 2014 to June 2016.Euro Surveill. 2019; 24: 1800627
- Emergence of carbapenem-resistant ST131 Escherichia coli carrying blaOXA-244 in Germany, 2019 to 2020.Eurosurveillance. 2020; 25: 2001815
- Transmission dynamics of ESBL-producing Escherichia coli clones in rehabilitation wards at a tertiary care centre.Clin Microbiol Infect. 2012; 18: E497-E505
- Emergence of ESBL-producing Escherichia coli ST131-C1-M27 clade colonizing patients in Europe.J Antimicrob Chemother. 2018; 73: 2973-2980
- Proton pump inhibitor use is associated with extended-spectrum β-lactamase–producing enterobacteriaceae rectal carriage at hospital admission: A cross-sectional study.CLINID. 2017; 64: 361-363
- Prevalence of multidrug-resistant organisms in nursing homes in Belgium in 2015.PLoS One. 2019; 14: e0214327
- Risk factors for extended-spectrum β-lactamase-producing Escherichia coli urinary tract infection in the community in Denmark: A case-control study.Clin Microbiol Infect. 2017; 23: 952-960
- Acid suppression medications during hospitalization as a risk factor for recurrence of Clostridioides difficile infection: Systematic review and meta-analysis.Clin Infect Dis. 2021; 73: e62-e68
- Acid-suppressive medication use and the risk for hospital-acquired pneumonia.JAMA. 2009; 301: 2120-2128
- Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: Cohort study.BMJ. 2019; 365: l1580
- Multimorbidities and overprescription of proton pump inhibitors in older patients.PLoS One. 2015; 10: e0141779
- Use of proton pump inhibitors with lack of diagnostic indications in 22 midwestern US skilled nursing facilities.J Am Med Dir Assoc. 2013; 14: 429-432
- Optimizing proton pump inhibitor use to reduce antimicrobial resistance rates?.Clin Infect Dis. 2017; 64: 1464-1465
- Effect of a proton pump inhibitor deprescribing guideline on drug usage and costs in long-term care.J Am Med Dir Assoc. 2016; 17: 673.e1-673.e4
Article info
Publication history
Footnotes
This work was supported by the Swiss National Sciences Foundation (grant number PZ00P3_179919 to PK) and the Federal Office of Public Health (grant number 18.011615).
The authors declare no conflicts of interest.
Identification
Copyright
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy